Every 424B that Kazia Therapeutics Limited (KZIA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KZIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KZIA filings page.
Registration covers 95,110 American Depositary Shares representing 47,555,000 ordinary shares, as set forth in a prospectus supplement to the Form F-1.
This supplement incorporates a Form 6-K dated March 19, 2026 attaching the company’s half‑year report for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as at 31 December 2025. The report discloses recent capital raises, including a private placement with net proceeds of approximately $46,509,833 and material issuances of ordinary shares and pre‑funded warrants closed in December 2025.
Kazia Therapeutics Limited files a prospectus supplement covering 266,666 American Depositary Shares, representing 133,333,000 ordinary shares, and updates investors using a newly furnished Form 6-K.
The attached report highlights encouraging early results from an ongoing Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer. Three patients treated with paxalisib-based regimens have shown meaningful clinical responses, including two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient.
Paxalisib in combination with pembrolizumab and chemotherapy has been generally well tolerated, with most adverse events deemed unlikely or unrelated to paxalisib and reported paxalisib-related events mainly mild to moderate. Kazia plans to activate additional clinical sites in 2026, aims to enroll twelve triple-negative breast cancer patients by the end of 2026, and anticipates topline data in early 2027.
Kazia Therapeutics Limited files a prospectus supplement covering 95,110 American Depositary Shares (ADSs), which represent 47,555,000 ordinary shares, to update its existing Form F‑1 prospectus with new clinical information from a recent Form 6‑K. The update centers on a Phase 1b study of paxalisib in late‑stage metastatic triple‑negative breast cancer (TNBC) in combination with pembrolizumab and chemotherapy.
In this program, three patients with metastatic TNBC treated with paxalisib‑based regimens have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated, with most adverse events considered unlikely or unrelated to the drug and only expected, mainly mild to moderate, paxalisib‑related side effects reported at the 30 mg daily dose.
Kazia plans to activate two additional clinical sites by April 2026 and two more in mid‑2026, targeting enrollment of twelve TNBC patients by the end of 2026 and a topline data readout in early 2027, while continuing broader development of paxalisib and other oncology assets.
Kazia Therapeutics Limited supplements its prospectus covering 232,956 American Depositary Shares, each representing 500 ordinary shares, with a new clinical update on paxalisib in metastatic triple-negative breast cancer (TNBC). The attached Form 6-K details preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy or with olaparib in advanced breast cancer. Three metastatic TNBC patients have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient, all remaining on treatment. Paxalisib has been generally well tolerated at a 30 mg daily dose, with mostly mild to moderate expected side effects and two serious adverse events reported as unrelated to paxalisib. Kazia plans to activate additional clinical sites in 2026, target enrollment of twelve TNBC patients by the end of 2026, and expects topline data in early 2027.
Kazia Therapeutics Limited has a prospectus supplement covering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares, and uses it to incorporate a new clinical update into its existing Form F-1 prospectus. The supplement attaches a Form 6-K that reports preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer.
The company notes three meaningful clinical responses so far: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated with mostly mild to moderate expected side effects, and Kazia plans to activate additional clinical sites in 2026, complete enrollment of twelve TNBC patients by the end of 2026, and target a topline data readout in early 2027.
Kazia Therapeutics Limited is registering for resale up to 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares, held by existing investors. These ADSs consist of ordinary shares and ADSs issuable upon exercise of pre-funded warrants originally sold in a prior private placement, and all sale proceeds will go to the selling shareholders, not the company.
Kazia is an oncology-focused biotech developing paxalisib for glioblastoma and other brain cancers, and EVT801 for solid tumors. In December 2025, the company completed a private placement of 4,530,854,000 ordinary shares and pre-funded warrants to purchase up to 938,490 ADSs, generating approximately $46.5 million in net proceeds, which management expects will fund operations into the second half of 2028. Nasdaq has also confirmed that Kazia’s ADSs remain in compliance with listing standards after a prior deficiency related to market value of listed securities.
Kazia Therapeutics Limited is updating a previously registered offering of 95,111 American Depositary Shares, representing 47,555,560 ordinary shares, via a prospectus supplement that incorporates its latest Form 6-K disclosure. The ADSs trade on Nasdaq under the symbol KZIA, and on November 17, 2025, the last reported sale price was $6.08 per ADS.
The attached Form 6-K explains that Kazia has not regained compliance with Nasdaq’s $35 million Market Value of Listed Securities requirement by the November 10, 2025 deadline. Nasdaq staff has issued a determination letter, and Kazia intends to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay any suspension or delisting. The company plans to present a compliance plan at the hearing but cautions there is no assurance the Panel will accept it or that it will ultimately meet all Nasdaq listing standards.
Kazia Therapeutics Limited updates its prospectus covering 1,770,000 American Depositary Shares, representing 885,000,000 ordinary shares, by incorporating a new Form 6-K. The update explains that Nasdaq previously notified the company its Market Value of Listed Securities was below the required $35 million from March 28, 2025 to May 9, 2025, triggering a compliance period that ended on November 10, 2025. On November 12, 2025, Nasdaq staff determined Kazia had not regained compliance and indicated its securities are subject to suspension or delisting unless a hearing is requested. Kazia plans to request a hearing before a Nasdaq Hearings Panel to present a plan to regain and sustain compliance, but there is no assurance the panel will accept the plan or that compliance will be restored.
Kazia Therapeutics Limited filed a prospectus supplement covering 274,666 American Depositary Shares, each representing ordinary shares, and uses it to attach and highlight a new Form 6-K disclosure.
The company reports it failed to regain compliance with Nasdaq’s Market Value of Listed Securities requirement, which mandates at least $35 million in market value under Nasdaq Listing Rule 5550(b)(2) by the November 10, 2025 compliance date. On November 12, 2025, Nasdaq staff issued a determination letter stating that Kazia had not met this requirement and that its securities are subject to suspension and potential delisting.
Kazia plans to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action while the hearing process and any Panel-granted extension period are pending. The company states it intends to demonstrate its ability to regain and sustain compliance, but cautions there is no assurance the Panel will accept its plan or that it will ultimately meet the listing standards.